We are live on ! Find out more
EUCR

Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR

Delisted

EUCR was delisted on the 26th of April, 2023.

Back to rankings

38 hedge funds and large institutions have $84.5M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

11% more capital invested

Capital invested by funds: $76.1M → $84.5M (+$8.48M)

3% more funds holding

Funds holding: 37 → 38 (+1)

Holders
38
Holders Change
+1
Holders Change %
+2.7%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
+$6.94M
2
MF
Magnetar Financial
Illinois
+$3.73M
3
MC
Meteora Capital
Florida
+$559K
4
FTCM
First Trust Capital Management
Illinois
+$386K
5
MSU
Mizuho Securities USA
New York
+$191K

Top Sellers

Rank Fund Capital Flow
1
ECU
Eisler Capital (UK)
United Kingdom
-$3.07M
2
SCM
Suvretta Capital Management
New York
-$990K
3
BCM
Basso Capital Management
Connecticut
-$430K
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$365K
5
Goldman Sachs
Goldman Sachs
New York
-$249K
Name Holding Trade Value Shares
Change 		Change in
Stake
CIM
26
Cowen Investment Management
New York
$501K – – –
Goldman Sachs
27
Goldman Sachs
New York
$307K -$249K -25,000 -45%
T. Rowe Price Associates
28
T. Rowe Price Associates
Maryland
$225K – – –
MSU
29
Mizuho Securities USA
New York
$192K +$191K +19,136 New
RL
30
RPO LLC
Connecticut
$191K +$189K +19,012 New
LCM
31
Landscape Capital Management
New Jersey
$129K +$128K +12,888 New
Morgan Stanley
32
Morgan Stanley
New York
$39K – – –
UBS Group
33
UBS Group
Switzerland
$39K +$17.2K +1,722 +78%
WCMNY
34
Westchester Capital Management (New York)
New York
$11K – – –
TRCT
35
Tower Research Capital (TRC)
New York
$10K -$20 -2 -0.2%
EC
36
Elequin Capital
New York
$5K +$4.98K +500 New
AI
37
Arena Investors
New York
$1.8K – – –
ECU
38
Eisler Capital (UK)
United Kingdom
– -$3.07M -310,294 Closed
SCM
39
Suvretta Capital Management
New York
– -$990K -99,999 Closed
BCM
40
Basso Capital Management
Connecticut
– -$430K -43,409 Closed
CM
41
Cohanzick Management
New York
– -$26K -2,649 Closed
OMC
42
Old Mission Capital
Illinois
– +$19K +1,907 +13%
1
2

EUCR Hedge Fund Activity: Q3 2022 in Review

38 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q3 2022, worth a combined $84.5M — up 11% from $76.1M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new EUCR positions and 4 closed out — a net gain of 1 holder — while 7 added to existing stakes and 5 trimmed.

The largest buyer was Glazer Capital LLC, adding an estimated $6.94M. The largest seller was Eisler Capital (UK), exiting entirely with an estimated $3.07M sold.

  • 38 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q3 2022, up from 37 in Q2 2022.
  • Funds reported $84.5M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q3 2022, up 11% quarter-over-quarter.
  • 5 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q3 2022 and 4 closed out, a net change of +1 holder.
  • The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares buyer in Q3 2022 was Glazer Capital LLC, an estimated $6.94M added.
  • The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q3 2022 was Eisler Capital (UK), an estimated $3.07M sold.

Based on aggregated 13F filings for Q3 2022.